Principal Financial Group Inc Provention Bio, Inc. Transaction History

Principal Financial Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$6.7 - $24.21 $450,407 - $1.63 Million	67,225 Added 28.12%	306,298 $7.38 Million
Q4 2022 Feb 09, 2023	BUY	$4.52 - $10.57 $1.01 Million - $2.37 Million	223,922 Added 1477.94%	239,073 $2.53 Million
Q3 2022 Nov 09, 2022	BUY	$3.43 - $5.62 $524 - $859	153 Added 1.02%	15,151 $68,000
Q2 2022 Aug 10, 2022	BUY	$3.65 - $7.3 $54,742 - $109,485	14,998 New	14,998 $60,000
Q4 2021 Feb 09, 2022	SELL	$5.59 - $7.39 $70,361 - $93,017	-12,587 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$5.66 - $8.33 $11,563 - $17,018	-2,043 Reduced 13.96%	12,587 $81,000
Q2 2021 Aug 10, 2021	SELL	$6.71 - $11.04 $61,678 - $101,479	-9,192 Reduced 38.59%	14,630 $123,000
Q1 2021 May 10, 2021	SELL	$10.12 - $19.45 $920 - $1,769	-91 Reduced 0.38%	23,822 $250,000
Q4 2020 Feb 08, 2021	BUY	$11.79 - $18.94 $161,982 - $260,216	13,739 Added 135.04%	23,913 $405,000
Q2 2020 Aug 05, 2020	BUY	$7.81 - $17.0 $79,458 - $172,958	10,174 New	10,174 $144,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.